Advances in the treatment of myasthenia gravis

Future Neurology

Volumn 7, Issue 6, 2012, Pages 701-708

  Gilhus, Nils Erik ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

acetylcholine receptor; autoimmunity; MuSK; myasthenia; myasthenia gravis; rituximab; thymus; treatment

Indexed keywords

3,4 DIAMINOPYRIDINE; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MUSK ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; TITIN ANTIBODY; UNCLASSIFIED DRUG;

ARTIFICIAL VENTILATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; EATON LAMBERT SYNDROME; HEART FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; LEUKOPENIA; LOW DRUG DOSE; MYASTHENIA; MYASTHENIA GRAVIS; MYASTHENIC CRISIS; NEONATAL MYASTHENIA GRAVIS; NONHUMAN; ONSET AGE; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT MONITORING; PHYSICAL ACTIVITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THYMECTOMY; THYMOMA; THYMUS HYPERPLASIA; TRAINING; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

EID: 84868654290     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.73     Document Type: Review

References (46)

1. Heldal AT, Owe JF, Gilhus NE et al. Seropositive myasthenia gravis; a nationwide epidemiologic study. Neurology 73, 150-151 (2009).
2. Andersen JB, Engeland A, Owe JF et al. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur. J. Neurol. 17, 1445-1450 (2010).
3. Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 76, 1526-1528 (2011).
4. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev. Neurother. 9, 351-358 (2009).
5. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiatr. 77, 203-207 (2006). (Pubitemid 43220844)
6. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis; past, present, and future. J. Clin. Invest. 116, 2843-2854 (2006). (Pubitemid 44684466)
7. Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17, 893-902 (2010).
8. Somnier FE, Engel PJH. The occurrence of anti-titin antibodies and thymomas; a population survey of MG 1970-1999. Neurology 59, 92-98 (2002). (Pubitemid 34742800)
9. Higuchi O, Hamuo J, Motomura M et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69, 418-422 (2011).
10. Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69, 445-451 (2012).
11. Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 131, 1940-1952 (2008). (Pubitemid 351957451)
12. Gilhus NE, Aarli JA, Janzen RWC, Otto HF, Matre R. Skeletal muscle antibodies in thymoma patients without myasthenia gravis. Acta Neurol. Scand. 69(Suppl. 98), S212-S213 (1984).
13. Kisand K, Lilic D, Casanova JL et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients; clinical and pathogenetic implications. Eur. J. Immunol. 41, 1517-1527 (2011).
14. Hapnes L, Willcox N, Oftedal B et al. Radioligand binding assay reveals distinct autoantibody preferences for type I interferons in APS 1 and myasthenia gravis subgroups. J. Clin. Immunol. 32, 230-237 (2012).
15. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis; reactivity and possible clinical signifcance. Arch. Neurol. 62, 442-446 (2005). (Pubitemid 40349480)
16. Cavalcante P, Serafni B, Rosicarelli B et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann. Neurol. 67, 726-738 (2010).
17. Meyer M, Höls AK, Liersch B et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann. Neurol. 70, 515-518 (2011).
18. Kakalacheva K, Maurer MA, Tackenberg B et al. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann. Neurol. 70, 508-514 (2011).
19. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann. NY Acad. Sci. 1132, 180-192 (2008). (Pubitemid 351841369)
20. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis; clinical fndings and response to treatment in two large cohorts. Muscle Nerve 44, 36-40 (2011).
21. Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis diagnosis and therapy. Autoimmune Dis. 2011, 973808 (2011).
22. Gilhus NE. Myasthenia and the neuromuscular junction. Curr. Opin. Neurol. 25(5), 523-529 (2012).
23. Kumar V, Kaminski HJ. Treatment of my asthenia gravis. Curr. Neurol. Neurosci. Rep. 11, 89-96 (2011).
24. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis and giving birth; a cohort study. Neurology 61, 1362-1366 (2003).
25. Benveniste O, Hilton-Jones D. The role of rituximab in the treatment of myasthenia gravis. Eur. Neurol. Rev. 5, 95-100 (2010).
26. Maddison P, McConville J, Farrugia ME et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatr. 82, 671-673 (2011).
27. Blum S, Gillis D, Brown H et al. Use and monitoring of low dose rituximab in myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 82, 659-663 (2011).
28. The Muscle Study Group. A trial of mycophenolatemofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71, 394-399 (2008).
29. Hehir MK, Burns TM, Alpers J et al. Mycophenolatemofetil in AChR-antibody-positive myasthenia gravis; outcomes in 102 patients. Muscle Nerve 41, 593-598 (2010).
30. Heckmann JM, Rawoot A, Bateman K et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 11, 97 (2011).
31. Tindall RS, Philips JT, Rollins JA, Wlls L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci. 681, 539-551 (1993). (Pubitemid 23233874)
32. Yoshikawa H, Kiuchi T, Saida T et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 82, 970-977 (2011).
33. Gronseth GS, Barohn RJ. Thymectomy for autoimmune myasthenia gravis; an evidence-based review. Neurology 55, 7-15 (2000).
34. Mantegazza R, Baggi F, Bernasconi P et al. Video-assisted thoracoscopic extended thymectomy and extended transsternalthymectomy (T-3b) in non-thymomatous myasthenia gravis patients; remission after 6years follow-up. J. Neurol. 212, 31-36 (2003). (Pubitemid 36700397)
35. Tellez-Zenteno JF, Hernandez-Ronquillo L, Salinas V et al. Myasthenia gravis and pregnancy; clinical implications and neonatal outcome. BMC Musculoskel. Dis. 5, 2474-2475 (2004).
36. Ferrero S, Pretta S, Nicoletti A et al. Myasthenia gravis; management issues during pregnancy. Eur. J. Obst. Gynecol. Reproduct. Biol. 121, 129-138 (2005). (Pubitemid 41074082)
37. Vincent A, Newland C, Brueton L et al. Arthrogryposis multiplex congenital with maternal autoantibodies specifc for a fetal antigen. Lancet 346, 24-25 (1995).
38. Hoff JM, Loane M, Gilhus NE, Rasmussen S, Daltveit AK. Arthrogryposis multiplex a congenital; an epidemiologic study of nearly 9 million births in 24 Eurocat registers. Eur. J. Obst. Gynecol. Reprod. Biol. 159, 347-350 (2011).
39. Aarli JA. Herzmyasthenie; myasthenia of the heart. Arch. Neurol. 66, 1322-1323 (2009).
40. Mandawat A, Mandawat A, Kaminski HJ et al. Outcome of plasmapheresis in myasthenia gravis; delayed therapy is not favorable. Muscle Nerve 43, 578-584 (2011).
41. Owe JF, Davidsen ES, Eide GE et al. Left ventricular long-axis function in myasthenia gravis. J. Neurol. 255, 1777-1784 (2008).
42. Liu CJ, Chang YS, Teng CJ et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan; a nationwide population-based study. Eur. J. Neurol. 19, 746-751 (2012).
43. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol. 41, 789-796 (1997). (Pubitemid 27249184)
44. Barth D, Nabavi N, Ng E et al. Comparison of intravenous immunoglobulin and PLEX in patients with myasthenia gravis. Neurology 76, 2017-2023 (2011).
45. Mandawat A, Kaminski H, Cutter G et al. Comparative analysis of therapeutic options used formyasthenia gravis. Ann. Neurol. 68, 797-805 (2010).
46. Gilhus NE. Acute treatment for myasthenia gravis. Nat. Rev. Neurol. 7, 132-134 (2011).